Barnaby 2.0 offers hope for AstraZeneca’s Aussie PR issues

Founder and principal at The Drill, Gerry McCusker, looks at a possible way forward for a vaccine’s image makeover.

AstraZeneca’s (AZ) COVID vaccine has a huge amount of PR equity to capitalise upon: genius scientists, Dame Sarah Gilbert, speed-of-light development, easy storage, at-cost price and at-volume provision, and a commitment to ongoing cheap supply of an anti-virus solution with a 75%+ efficacy rate. But down under, no-one’s talking up that. For after sporadic safety issues, multiple brand attacks, an EU legal action plus a seemingly tame PR defence of its brand reputation (as well as many puzzling internal mis-steps), many Australians are now eyeing the AZ vaccine with cynical suspicion.

Without exploring the full A-to-Z of AZ’s woes, AstraZeneca clearly needs to overcome its negative PR problems in Australia. And flamboyant Aussie politician Barnaby Joyce could be an inspirational, albeit unlikely, hero for the AZ team.

Be a member to keep reading

Join Mumbrella Pro to access the Mumbrella archive and read our premium analysis of everything under the media and marketing umbrella.

Become a member

Get the latest media and marketing industry news (and views) direct to your inbox.

Sign up to the free Mumbrella newsletter now.

"*" indicates required fields

 

SUBSCRIBE

Sign up to our free daily update to get the latest in media and marketing.